ArticleJournal of virology2003
Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.Digestive diseases and sciences · 2007Trial
- Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection.Antimicrobial agents and chemotherapy · 2014Article
- Distribution of HCV genotypes in the populations of inmates in polish prison potulice and patients hospitalised in bydgoszcz.Hepatitis monthly · 2014Article
- Within-host dynamics of the hepatitis C virus quasispecies population in HIV-1/HCV coinfected patients.PloS one · 2011Article
- The hepatitis C virus 5'UTR genomic region remains highly conserved under HAART: a 4- to 8-year longitudinal study from HCV/HIV co-infected patients.AIDS research and human retroviruses · 2010Article
- Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.Journal of virology · 2009Review
- Genetic divergence of hepatitis C virus: the role of HIV-related immunosuppression.Journal of acquired immune deficiency syndromes (1999) · 2008Article
- Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients.Journal of acquired immune deficiency syndromes (1999) · 2008Article
- Trends for genetic variation of Hepatitis C Virus quasispecies in Human Immunodeficiency virus-1 coinfected patients.Virus research · 2007Article
- Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART).Hepatology (Baltimore, Md.) · 2007Article
- Pathogenesis of HIV-HCV Coinfection.Current infectious disease reports · 2007Article
- Therapeutic issues in HIV/HCV-coinfected patients.Journal of viral hepatitis · 2007Review
- Influence of increased CD4 cell counts on the genetic variability of hepatitis C virus in patients co-infected with human immunodeficiency virus I.Journal of biomolecular techniques : JBT · 2006Article
- Plasma and liver hepatitis C virus variability in patients coinfected with human immunodeficiency virus.Journal of clinical microbiology · 2006Article
- Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus.Journal of virology · 2006Article
- Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis.Virology journal · 2005Article
- Wide range of quasispecies diversity during primary hepatitis C virus infection.Journal of virology · 2005Article
- Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection.HIV medicine · 2005Review
- Differing patterns of liver disease progression and hepatitis C virus (HCV) quasispecies evolution in children vertically coinfected with HCV and human immunodeficiency virus type 1.Journal of clinical microbiology · 2004Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study analyzes the effect of highly active antiretroviral therapy (HAART), and thus immunologic status, on hepatitis C virus (HCV) load and quasispecies diversity in patients coinfected with the human immunodeficiency virus (HIV) and HCV. Three cohorts of coinfected patients were analyzed retrospectively over a period of 7 to 10 months: group A was antiretroviral drug naïve at baseline and then on HAART for the remainder of the study, group B did not receive antiretroviral therapy at any point, and group C was on HAART for the entire study. HCV quasispecies diversity was analyzed by sequencing hypervariable region 1. In a longitudinal analysis, there was no significant change from baseline in any immunologic, virologic, or quasispecies parameter in any of the three groups. However, in comparison to groups A and B, group C had significantly higher CD4+- and CD8+-cell counts, a trend toward a higher HCV load, and significantly increased number of HCV clones, entropy, genetic distance, and ratio of nonsynonymous substitutions per nonsynonymous site to synonymous substitutions per synonymous site (Ka/Ks). In addition, CD4+-cell count was positively correlated with HCV load, genetic distance, and Ka. Interestingly, patients infected with HCV genotype 2 or 3 had a significantly higher CD4+-cell count, HCV load, genetic distance, and Ka/Ks than those infected with genotype 1. These results suggest that there is no immediate effect of HAART on HCV but that, with prolonged HAART, immune restoration results in an increase in HCV load and quasispecies diversity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.